Skip to main content
CSL Behring News)

Global Newsroom

Recent News Releases


Coronavirus Information

During the COVID-19 outbreak, CSL is here for our patients and our larger world community.

Ukraine Information

CSL condemns the invasion of Ukraine and we are supporting multiple humanitarian relief efforts to help those impacted by this unjust act.

Latest CSL News

Latest CSL News

CSL Welcomes US Court Ruling

11 May 2022

Statement attributable to Greg Boss, Executive Vice President - Legal, and CSL Limited Group General Counsel.

CSL recognised in AFR Best Places to Work.

26 Apr 2022

CSL ranked fourth on the Health Industry list, from a total of more than 750 organisations nominated in all sectors across Australia and New Zealand.

FDA Clearance of Plasma Collection Technology

11 Mar 2022

CSL Plasma U.S. collection centers are preparing to undergo implementation of newly cleared Rika Plasma Donation System, with limited market release beginning in Colorado centers.

Forbes Ranks CSL Among America's Best Employers

02 Mar 2022

With 25,000 global employees, CSL is one of 500 Large Employers recognized across 25 industry sectors

CSL Publishes Vifor Offer Prospectus

18 Jan 2022

CSL Behring AG Publishes Offer Prospectus On Public Tender Offer For All Publicly Held Shares Of Vifor Pharma Ltd.

CSL Joins StartX Community

30 Nov 2021

Through the StartX partnership, CSL will access an ecosystem of early stage biotech, medtech and digital healthcare ventures, exploring opportunities to collaborate around disruptive technologies and build relationships with entrepreneurial founders.

CSL Committed to AZ COVID Vaccine

14 Oct 2021

CSL Reaffirms Commitment to Manufacture AstraZeneca COVID Vaccine into 2022

CSL Requires COVID-19 Vaccination

08 Oct 2021

CSL Requires COVID-19 Vaccination for On-Site Employees and Visitors

Applications Open for Fellowships

01 Jun 2021

$2.5 Million Funding Available to Australian Biomedical Researchers

CSL welcomes the Patent Box Policy

12 May 2021

New Patent Box policy will benefit domestic commercialisation of medical research

CSL welcomes domestic mRNA vaccine development

12 May 2021

Onshore mRNA manufacturing will build Australian capability for next generation vaccine technologies

CSL Behring Announces Agreement with uniQure

06 May 2021

Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein that prevents excessive bleeding.

uniQure will complete the Phase 3 HOPE-B trial and scale up manufacture for initial commercial supply under an agreed plan with CSL Behring.

2020 RAI Awardees Announced

29 Apr 2021

Four Australian Research Programs to be Fast-Tracked in Partnership with CSL

Media Contacts

Christina Hickie

CSL Limited
Senior Manager, Communications
Phone: +61 429 609 762

News & Press Release Archive